An Evidence-Based Review of Systemic Therapies for Moderate-to-Severe Plaque Psoriasis in the Pediatric Population

Authors

  • Vimal H. Prajapati, MD, FRCPC

Abstract

Psoriasis is a chronic immune-mediated inflammatory condition of the skin that affects 2-3% of the general population. Onset during childhood and adolescence occurs in up to one-third of cases. The plaque subtype is most common.

Moderate-to-severe plaque psoriasis can have a significant impact on quality of life for affected pediatric patients and their adult caregivers. As a result, systemic therapy is often required. However, selecting the right treatment in this special population can be a challenge, given the paucity of data, standardized international guidelines, and approved options. 

The aim of this article is to review the available evidence for systemic therapies used to treat moderate-to-severe plaque psoriasis in pediatric patients. In-depth discussion will be limited to the most rigorous studies only.

Author Biography

Vimal H. Prajapati, MD, FRCPC

Dr. Vimal H. Prajapati is a Clinical Assistant Professor at the University of Calgary, co-creator of The Dermatology Philosophy, as well as co-founder and co-director of the Skin Health & Wellness Centre, Dermphi Centre, Dermatology Learning Institute, Dermatology Research Institute, Dermphi Therapeutics, and D&P Commercial Group. Additionally, he has started several subspecialty initiatives, including multidisciplinary clinics for pediatric morphea, pediatric scleroderma, and pediatric psoriasis in Calgary, rapid access clinics for psoriasis and eczema in Calgary, as well as rural outreach clinics for psoriasis and eczema in Medicine Hat.

References

Parisi R, Symmons DPM, Griffiths CEM, Ashcroft DM. Global epidemiology of psoriasis: a systemic review of incidence and prevalence. J Invest Dermatol. 2013;133(2):377-385.

De Jager ME, de Jong EM, Meeuwis KA, et al. No evidence found that childhood onset of psoriasis influences disease severity, future body mass index or type of treatments used. J Eur Acad Dermatol Venereol. 2010;24(11):1333-1339.

Tollefson MM, Crowson CS, McEvoy MT, Kremers HM. Incidence of psoriasis in children: a population-based study. J Am Acad Dermatol. 2010;62(6):979-987.

Randa H, Todberg T, Skov L, Larsen LS, Zachariae R. Health-related quality of life in children and adolescents with psoriasis: a systematic review and meta-analysis. Acta Derm Venereol. 2017;97(5):555-563.

Remrod C, Sjostrom K, Svensson A. Psychological differences between early- and late-onset psoriasis: a study of personality traits, anxiety and depression in psoriasis. Br J Dermatol. 2013;169(2):344-350.

Lansang P, Bergman JN, Fiorillo L, et al. Management of pediatric plaque psoriasis using biologics. J Am Acad Dermatol. 2020;82(1):213-221.

Bronckers IMGJ, Seyger MMB, West DP, et al. Safety of systemic agents for the treatment of pediatric psoriasis. JAMA Dermatol. 2017;153(11):1147-1157.

Ergun T, Seckin Gencosmanoglu D, Alpsoy E, et al. Efficacy, safety and drug survival of conventional agents in pediatric psoriasis: a multicenter, cohort study. J Dermatol. 2017;44(6):630-634.

Menter A, Cordoro KM, Davis DRM, et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients. J Am Acad Dermatol. 2020;82(1):161-201.

Papp KA, Thaci D, Marcoux D, et al. Efficacy and safety of adalimumab every other week versus methotrexate once weekly in children and adolescents with severe chronic plaque psoriasis: a randomised, double-blind, phase 3 trial. Lancet. 2017;390(10089):40-49.

Paller AS, Hong Y, Becker EM, et al. Pharmacokinetics and safety of apremilast in pediatric patients with moderate to severe plaque psoriasis: results from a phase 2 open-label study. J Am Acad Dermatol. 2020;82(2):389-397.

Efficacy and Safety Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis; ClinicalTrials.gov Identifier: NCT03701763; Accessed June 15, 2020.

A Long-term Extension Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis; ClinicalTrials.gov Identifier: NCT04175613; Accessed June 15, 2020.

Paller AS, Siegfried EC, Langley RG, et al. Etanercept treatment for children and adolescents with plaque psoriasis. New Engl J Med. 2008;358(3):241-251.

Langley RG, Paller AS, Hebert AA, et al. Patient-reported outcomes in pediatric patients with psoriasis undergoing etanercept treatment: 12-week results from a phase III randomized controlled trial. J Am Acad Dermatol. 2011;64(1):64-70.

Siegfried EC, Eichenfield LF, Paller AS, Pariser D, Creamer K, Kricorian G. Intermittent etanercept therapy in pediatric patients with psoriasis. J Am Acad Dermatol. 2010;63(5):769-774.

Paller AS, Siegfried EC, Eichenfield LF, et al. Long-term etanercept in pediatric patients with plaque psoriasis. J Am Acad Dermatol. 2010;63(5):762-768.

Paller AS, Siegfried EC, Pariser DM, et al. Long-term safety and efficacy of etanercept in children and adolescents with plaque psoriasis. J Am Acad Dermatol. 2016;74(2):280-287.

Thaci D, Papp KA, Marcoux D, et al. Sustained long-term efficacy and safety of adalimumab in paediatric patients with severe chronic plaque psoriasis from a randomized, double-blind, phase III study. Br J Dermatol. 2019;181(6):1177-1189.

Landells I, Marano C, Hsu MC, et al. Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: results of the randomized phase 3 CADMUS study. J Am Acad Dermatol. 2015;73(4):594-603.

Philipp S, Menter A, Nikkels AF, et al. Ustekinumab for the treatment of moderate-to-severe plaque psoriasis in paediatric patients (≥ 6 to < 12 years of age): efficacy, safety, pharmacokinetic and biomarker results from the open-label CADMUS Jr study. Br J Dermatol. 2020 Mar 16; doi:10.1111/bjd.19018. Online ahead of print.

Paller AS, Seyger MMP, Alejandro Magarinos G, et al. Efficacy and safety of ixekizumab in a phase III, randomized, double-blind, placebo-controlled study, in paediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS). Br J Dermatol. 2020 Apr 21; doi: 10.1111/bjd.19147. Online ahead of print.

Pediatric Study in Children and Adolescents With Severe Plaque Psoriasis; ClinicalTrials.gov Identifier: NCT02471144; Accessed June 15, 2020.

Study to Assess the Long-term Safety, Tolerability, Efficacy of Secukinumab in Pediatric Patients of Age 6 to <18 Years, With Moderate to Severe Plaque Psoriasis; ClinicalTrials.gov Identifier: NCT03668613; Accessed June 15, 2020.

An Open-label, Single-dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Brodalumab in Pediatric Subjects; ClinicalTrials.gov Identifier: NCT03240809; Accessed June 15, 2020.

A Study to Evaluate the Efficacy, Safety, and Drug Concentration of Certolizumab Pegol (CZP) in Children and Adolescent Study Participants With Moderate to Severe Chronic Plaque Psoriasis (PSO) (CIMcare); ClinicalTrials.gov Identifier: NCT04123795; Accessed June 15, 2020.

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants (PROTOSTAR); ClinicalTrials.gov Identifier: NCT03451851; Accessed June 15, 2020.

A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms; ClinicalTrials.gov Identifier: NCT04435600; Accessed June 15, 2020.

Published

2020-07-01

How to Cite

1.
Prajapati VH. An Evidence-Based Review of Systemic Therapies for Moderate-to-Severe Plaque Psoriasis in the Pediatric Population. Can Dermatol Today [Internet]. 2020 Jul. 1 [cited 2024 Dec. 6];1(3):12-8. Available from: https://canadiandermatologytoday.com/article/view/1-3-prajapati

Issue

Section

Articles